Authors
Pin-Jie Li, Tzu-Yi Liao, Yen-Ling Liu, Zih-Yu Jhuang, En-Shuo Liu, Bo-Cheng Huang, Shih-Ting Hong, Chia-Ching Lee, Yu-Tung Chen, Chiao-Yun Chen, Fang-Ming Chen, Tian-Lu Cheng, Wen-Wei Lin, Kai-Wen Ho
Published in
Translational research : the journal of laboratory and clinical medicine. Oct 30, 2026. Epub Oct 30, 2026.
Abstract
PEGylated asparaginase (PEG-ASNase) is standard for lymphoma but limited by poor tumor localization and stromal niche-conferred resistance.
We developed a bispecific antibody (bsAb), CD20 Ab-mPEG scFv, targeting CD20 and mPEG. Dual-binding and cytotoxicity were assessed via flow cytometry, confocal microscopy, and co-culture with HS-5 stromal cells. In vivo efficacy and biodistribution were evaluated in Raji-bearing SCID mice.
The bsAb facilitated sustained anchoring of PEG-ASNase on lymphoma cells. In mono-culture assays at 5.3 IU mL⁻¹ PEG-ASNase, combination treatment reduced cell viability to 40.5% compared to 86.2% for PEG-ASNase alone (p < 0.0001). Furthermore, in the HS-5 stromal co-culture system, the combination strategy effectively attenuated stromal cell-conferred protection, reducing viability to 62.7% versus 80.5% for PEG-ASNase alone (p < 0.0001). In vivo, bsAb pre-targeting (24h) led to 1.8-fold higher tumor retention and 62% reduction in tumor volume (p < 0.0001) without additional toxicity compared with PEG-ASNase alone.
This bsAb strategy enhances PEG-ASNase pharmacodynamics and attenuates stromal niche-mediated protection, offering a promising targeted metabolic approach for CD20-positive lymphoma.
PMID:
42962969
Bibliographic data and abstract were imported from PubMed on 31 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0